D&C, Conization, Laparoscopy and Tubal Interruption DRG Reimbursement

D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

DRG 744 includes inpatient admissions involving dilation and curettage, cervical conization, laparoscopy, and tubal interruption when a Major Complication or Comorbidity or Complication or Comorbidity is present, affecting resource intensity. This Diagnosis-Related Group is important for inpatient reimbursement because the presence of a Major Complication or Comorbidity or Complication or Comorbidity changes payment relative to less complex cases.

Customize your policy alerts

Sign up for D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 744 Overview

DRG 744 covers inpatient admissions for dilation and curettage, cervical conization, laparoscopy, and tubal interruption when a Major Complication or Comorbidity or Complication or Comorbidity is present. This Diagnosis-Related Group bundles related gynecologic procedural care and associated inpatient resources for Medicare beneficiaries. It matters for Medicare payment because presence of a Major Complication or Comorbidity or Complication or Comorbidity elevates relative resource use and reimbursement compared with cases without these diagnoses. Hospitals use the Diagnosis-Related Group assignment to determine base Medicare inpatient payments for these procedures.

D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 744 Overview

National Payment Rates

Across commercial payers the observed rate range spans from about $370 up to $62K, with the widest spread between minimum and maximum seen in Anthem. Refer to the payer table and the accompanying chart below for payer-specific quartiles and distribution details. Payer labels shown include Blue Cross Blue Shield, Anthem, Cigna, and Aetna.

The CMS 2023 data are national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 744 in 2023. Values reflect national-level averages and case volumes for Medicare FFS beneficiaries.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$19K	$97K	$16K	1.1K

Patient Population

This DRG’s patient population is mixed but leans toward working-age adults rather than predominantly Medicare-age beneficiaries. Medicare discharges represent a portion of overall volume (1,116 total Medicare discharges in 2023), indicating both commercial and Medicare payers cover these admissions. Expect a mix of privately insured (working-age) and Medicare-age patients rather than a population exclusively Medicare-age.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates in Alaska range from $32K to $82K, reflecting substantial dispersion across carriers. Cigna’s $82K maximum and $49K mean stand out as the most notable deviation above national averages, while Anthem and Blue Cross Blue Shield cluster at $32K on the low end. See the table and chart below for payer-level detail.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska at $82K, while Anthem and BCBS both report the lowest observed rate at $32K.
Alaska’s mean of $49K (Cigna) sits notably above national medians for similar DRGs, indicating a meaningful upward deviation driven by Cigna’s rates.

Clinical Trials

Trials comparing surgical techniques and intraoperative management for procedures such as dilation and curettage (D&C), cervical conization, diagnostic or operative laparoscopy, and tubal interruption. These studies enroll hospitalized reproductive-age and peri‑menopausal women undergoing these procedures for indications like abnormal uterine bleeding, cervical dysplasia, ectopic pregnancy evaluation, or sterilization, and evaluate outcomes such as operative time, blood loss, anesthesia approaches, conversion to open surgery, and perioperative complication rates. Results inform surgeons and hospitals about best practices to reduce length of stay, resource use, and complication-related costs that directly affect DRG-based reimbursements.
Comparative effectiveness studies of perioperative infection prevention, hemorrhage control, and thromboprophylaxis strategies in this mixed-surgery cohort. These pragmatic trials or registry analyses assess different antibiotic regimens, local hemostatic agents, uterotonic use, and VTE prophylaxis protocols in patients with varying comorbidities (eg, coagulopathy, obesity, diabetes) to measure rates of postoperative infection, reoperation, transfusion, and readmission. Findings are relevant to payers and providers because they target preventable complications and readmissions that drive CC/MCC assignment and higher reimbursement tiers, and can support standardized protocols to improve outcomes and lower avoidable costs.
Post-discharge outcomes and patient-reported outcomes research examining recovery trajectories, fertility and quality-of-life impacts, and long-term complications after these gynecologic procedures. Cohort studies and prospective observational research follow patients discharged under DRG 744 to quantify time to return to baseline function, incidence of chronic pelvic pain, subsequent fertility interventions, and health care utilization over 30–90 days. This area matters for discharge planning, post-acute care allocation, and payer assessments of downstream costs and value, helping health systems optimize care pathways and identify patients who may benefit from intensified follow-up to prevent costly late complications.

Trials comparing surgical techniques and intraoperative management for procedures such as dilation and curettage (D&C), cervical conization, diagnostic or operative laparoscopy, and tubal interruption. These studies enroll hospitalized reproductive-age and peri‑menopausal women undergoing these procedures for indications like abnormal uterine bleeding, cervical dysplasia, ectopic pregnancy evaluation, or sterilization, and evaluate outcomes such as operative time, blood loss, anesthesia approaches, conversion to open surgery, and perioperative complication rates. Results inform surgeons and hospitals about best practices to reduce length of stay, resource use, and complication-related costs that directly affect DRG-based reimbursements.
Comparative effectiveness studies of perioperative infection prevention, hemorrhage control, and thromboprophylaxis strategies in this mixed-surgery cohort. These pragmatic trials or registry analyses assess different antibiotic regimens, local hemostatic agents, uterotonic use, and VTE prophylaxis protocols in patients with varying comorbidities (eg, coagulopathy, obesity, diabetes) to measure rates of postoperative infection, reoperation, transfusion, and readmission. Findings are relevant to payers and providers because they target preventable complications and readmissions that drive CC/MCC assignment and higher reimbursement tiers, and can support standardized protocols to improve outcomes and lower avoidable costs.
Post-discharge outcomes and patient-reported outcomes research examining recovery trajectories, fertility and quality-of-life impacts, and long-term complications after these gynecologic procedures. Cohort studies and prospective observational research follow patients discharged under DRG 744 to quantify time to return to baseline function, incidence of chronic pelvic pain, subsequent fertility interventions, and health care utilization over 30–90 days. This area matters for discharge planning, post-acute care allocation, and payer assessments of downstream costs and value, helping health systems optimize care pathways and identify patients who may benefit from intensified follow-up to prevent costly late complications.

OpenPayer

D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

Sign up for D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 744 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

Sign up for D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 744 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References